Literature DB >> 32034799

Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.

Anwesha Sanyal1, Mark P DeAndrade1, Hailey S Novis1, Steven Lin1, Jianjun Chang2, Nathalie Lengacher3, Julianna J Tomlinson3, Malú G Tansey4, Matthew J LaVoie1.   

Abstract

BACKGROUND: Autosomal recessive mutations in the glucocerebrosidase gene, Beta-glucocerebrosidase 1 (GBA1), cause the lysosomal storage disorder Gaucher's disease. Heterozygous carriers of most GBA1 mutations have dramatically increased Parkinson's disease (PD) risk, but the mechanisms and cells affected remain unknown. Glucocerebrosidase expression is relatively enriched in astrocytes, yet the impact of its mutation in these cells has not yet been addressed.
OBJECTIVES: Emerging data supporting non-cell-autonomous mechanisms driving PD pathogenesis inspired the first characterization of GBA1-mutant astrocytes. In addition, we asked whether LRRK2, likewise linked to PD and enriched in astrocytes, intersected with GBA1 phenotypes.
METHODS: Using heterozygous and homozygous GBA1 D409V knockin mouse astrocytes, we conducted rigorous biochemical and image-based analyses of lysosomal function and morphology. We also examined basal and evoked cytokine response at the transcriptional and secretory levels.
RESULTS: The D409V knockin astrocytes manifested broad deficits in lysosomal morphology and function, as expected. This, however, is the first study to show dramatic defects in basal and TLR4-dependent cytokine production. Albeit to different extents, both the lysosomal dysfunction and inflammatory responses were normalized by inhibition of LRRK2 kinase activity, suggesting functional intracellular crosstalk between glucocerebrosidase and LRRK2 activities in astrocytes.
CONCLUSIONS: These data demonstrate novel pathologic effects of a GBA1 mutation on inflammatory responses in astrocytes, indicating the likelihood of broader immunologic changes in GBA-PD patients. Our findings support the involvement of non-cell-autonomous mechanisms contributing to the pathogenesis of GBA1-linked PD and identify new opportunities to correct these changes with pharmacological intervention.
© 2020 International Parkinson and Movement Disorder Society. © 2020 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  GBA1; LRRK2; Parkinson's disease; astrocyte dysfunction; neuroinflammation

Mesh:

Substances:

Year:  2020        PMID: 32034799      PMCID: PMC8167931          DOI: 10.1002/mds.27994

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  94 in total

1.  Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains.

Authors:  Robert G Nagele; Michael R D'Andrea; H Lee; Venkateswar Venkataraman; Hoau-Yan Wang
Journal:  Brain Res       Date:  2003-05-09       Impact factor: 3.252

2.  Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.

Authors:  Gilad Yahalom; Lior Greenbaum; Simon Israeli-Korn; Tsvia Fay-Karmon; Vered Livneh; Jennifer A Ruskey; Léanne Roncière; Armaghan Alam; Ziv Gan-Or; Sharon Hassin-Baer
Journal:  Parkinsonism Relat Disord       Date:  2018-12-13       Impact factor: 4.891

3.  Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates.

Authors:  Laura A Volpicelli-Daley; Kelvin C Luk; Virginia M-Y Lee
Journal:  Nat Protoc       Date:  2014-08-14       Impact factor: 13.491

Review 4.  The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.

Authors:  J Schapansky; J D Nardozzi; M J LaVoie
Journal:  Neuroscience       Date:  2014-10-02       Impact factor: 3.590

5.  Comparison of RNase A, a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene.

Authors:  B D Theophilus; T Latham; G A Grabowski; F I Smith
Journal:  Nucleic Acids Res       Date:  1989-10-11       Impact factor: 16.971

6.  A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarizations: a meta-analysis.

Authors:  D M Salerno; K J Gillingham; D A Berry; M Hodges
Journal:  Am Heart J       Date:  1990-08       Impact factor: 4.749

7.  Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.

Authors:  Roy N Alcalay; Oren A Levy; Cheryl C Waters; Stanley Fahn; Blair Ford; Sheng-Han Kuo; Pietro Mazzoni; Michael W Pauciulo; William C Nichols; Ziv Gan-Or; Guy A Rouleau; Wendy K Chung; Pavlina Wolf; Petra Oliva; Joan Keutzer; Karen Marder; Xiaokui Zhang
Journal:  Brain       Date:  2015-06-27       Impact factor: 13.501

8.  LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase.

Authors:  David Reczek; Michael Schwake; Jenny Schröder; Heather Hughes; Judith Blanz; Xiaoying Jin; William Brondyk; Scott Van Patten; Tim Edmunds; Paul Saftig
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

9.  Atp13a2 Deficiency Aggravates Astrocyte-Mediated Neuroinflammation via NLRP3 Inflammasome Activation.

Authors:  Chen Qiao; Nuo Yin; Huan-Yu Gu; Jia-Lei Zhu; Jian-Hua Ding; Ming Lu; Gang Hu
Journal:  CNS Neurosci Ther       Date:  2016-02-05       Impact factor: 5.243

10.  LRRK2 transport is regulated by its novel interacting partner Rab32.

Authors:  Dieter Waschbüsch; Helen Michels; Swantje Strassheim; Edith Ossendorf; Daniel Kessler; Christian Johannes Gloeckner; Angelika Barnekow
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

View more
  29 in total

Review 1.  Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.

Authors:  Mattia Volta
Journal:  Neurotherapeutics       Date:  2022-09-09       Impact factor: 6.088

2.  High-throughput analysis of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosing.

Authors:  Robert N Plasschaert; Mark P DeAndrade; Fritz Hull; Quoc Nguyen; Tara Peterson; Aimin Yan; Mariana Loperfido; Cristina Baricordi; Luigi Barbarossa; John K Yoon; Yildirim Dogan; Zeenath Unnisa; Jeffrey W Schindler; Niek P van Til; Luca Biasco; Chris Mason
Journal:  Mol Ther       Date:  2022-05-25       Impact factor: 12.910

3.  LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease.

Authors:  Maria Kedariti; Emanuele Frattini; Pascale Baden; Susanna Cogo; Laura Civiero; Elena Ziviani; Gianluca Zilio; Federico Bertoli; Massimo Aureli; Alice Kaganovich; Mark R Cookson; Leonidas Stefanis; Matthew Surface; Michela Deleidi; Alessio Di Fonzo; Roy N Alcalay; Hardy Rideout; Elisa Greggio; Nicoletta Plotegher
Journal:  NPJ Parkinsons Dis       Date:  2022-07-19

Review 4.  Astrocytes in Neurodegeneration: Inspiration From Genetics.

Authors:  Jingxuan Huang; Chunyu Li; Huifang Shang
Journal:  Front Neurosci       Date:  2022-06-24       Impact factor: 5.152

5.  WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson's Disease Monocytes.

Authors:  Rebecca L Wallings; Laura P Hughes; Hannah A Staley; Zachary D Simon; Nikolaus R McFarland; Roy N Alcalay; Alicia Garrido; María José Martí; Eduardo Tolosa Sarró; Nicolas Dzamko; Malú Gámez Tansey
Journal:  Front Cell Neurosci       Date:  2022-06-09       Impact factor: 6.147

Review 6.  Immunogenetic Determinants of Parkinson's Disease Etiology.

Authors:  Pin-Jui Kung; Inas Elsayed; Paula Reyes-Pérez; Sara Bandres-Ciga
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 7.  Microglia and astrocyte dysfunction in parkinson's disease.

Authors:  Tae-In Kam; Jared T Hinkle; Ted M Dawson; Valina L Dawson
Journal:  Neurobiol Dis       Date:  2020-07-28       Impact factor: 5.996

Review 8.  Neuroinflammation in Gaucher disease, neuronal ceroid lipofuscinosis, and commonalities with Parkinson's disease.

Authors:  Laetitia Francelle; Joseph R Mazzulli
Journal:  Brain Res       Date:  2022-01-19       Impact factor: 3.610

9.  LRRK2 Kinase Inhibition Rescues Deficits in Lysosome Function Due to Heterozygous GBA1 Expression in Human iPSC-Derived Neurons.

Authors:  Anwesha Sanyal; Hailey S Novis; Emile Gasser; Steven Lin; Matthew J LaVoie
Journal:  Front Neurosci       Date:  2020-05-15       Impact factor: 4.677

10.  Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.

Authors:  Linn Streubel-Gallasch; Veronica Giusti; Michele Sandre; Isabella Tessari; Nicoletta Plotegher; Elena Giusto; Anna Masato; Ludovica Iovino; Ilaria Battisti; Giorgio Arrigoni; Derya Shimshek; Elisa Greggio; Marie-Eve Tremblay; Luigi Bubacco; Anna Erlandsson; Laura Civiero
Journal:  Mol Neurobiol       Date:  2021-02-24       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.